This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade.
2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. 7 Recent clinical studies highlight promising developments in c-MET-targeting ADCs for NSCLC.
The high prevalence of breast cancer is a global health concern, but there are no safe or effective treatments for it at its advanced stages. These facts urge the development of novel treatment strategies. This treatment strategy was tested in vivo with the orthotopic EMT6 breast tumor model in female balb/cJ mice.
This ebook delves into the intricate world of cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and groundbreaking advancements in gene editing, featuring insightful interviews with renowned experts in the field.
What key findings about stem cell behaviour, differentiation and integration within host tissues impact the development of stem cell therapies? Additionally, ADSCs possess immunomodulatory properties, enabling them to modulate immuneresponses and promote tissue healing.
Science (2024) Related content New gene delivery vehicle shows promise for human brain gene therapy My Quest to Cure Prion Disease — Before It’s Too Late | Sonia Vallabh | TED Prion diseases lead to rapid neurodegeneration and death and are caused by misshapen versions of the prion protein in the brain. Credit: Neumann EN, Bertozzi TM, et al.
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
Research 1 has shown that neutrophil elastase selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilises adaptive immunity, and avoids resistance mechanisms. Could you provide insights into the driving factors behind exploring novel treatments for cancer types?
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immuneresponse’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.
Terpenes are compounds that inhibit the growth of Leishmania spp, Schistosoma spp, and Echinococcus spp, cause changes in parasite ultrastructure, inhibit enzyme activity, and modulate the immuneresponse. Their use in combination therapy decreases the concentration of the reference drug used.
Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months.
In the realm of immunology, researchers are constantly striving to unlock the intricate secrets of the human immune system. Among the many remarkable components that make up this complex defence network, T cells have emerged as powerful guardians, orchestrating an array of immuneresponses with great precision.
Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. However, cell-based therapies are intended to leverage those healthy cells via transplant to regenerate damaged tissue.
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immuneresponse’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? Long-term protection against tumour recurrence in AMP-treated mice was associated with antigen spreading to additional tumour-associated antigens not targeted by the treatment.
doi: 10.1038/s41590-024-01792-2 (2024) Scientists used a microscope to visualize an immunity hub (yellow and green) in human lung tumor tissue (blue). Networks of cells are critical in mediating immuneresponses. How do immune cells organize within tumors to effectively eliminate cancer cells? Nature Immunology.
Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Stem cell transplants primarily help the immuneresponse through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.”
Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.
Last week DNA Science covered a setback in a clinical trial of a gene therapy for Duchenne muscular dystrophy (DMD). Also recently, FDA’s Cellular, Tissue, and Gene Therapies Advisory Committe turned down a stem cell treatment for amyotrophic lateral sclerosis, aka ALS, Lou Gehrig’s disease, or motor neuron disease.
In the final chapter of my 2012 book The Forever Fix: Gene Therapy and the Boy Who Saved It , I predicted that the technology would soon expand well beyond the rare disease world. Gene therapy clearly hasn’t had a major impact on health care, offering extremely expensive treatments for a few individuals with rare diseases.
Manguso, who’d recently graduated from college and was conducting research at the University of Copenhagen as a Fulbright scholar, moved back to the Boston area to be with his mother as she underwent treatment. His mother had a presentation of the disease that suggested her immune system was already on the job.
Better activation of innate and adaptive immuneresponses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.
The journey toward effective treatments has been long and evolving, with recent breakthroughs offering new hope to those living with this challenging condition. From Coal Tar to Biologics: A Historical Perspective The history of psoriasis treatment is as old as the condition itself, with records dating back to ancient times.
In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immuneresponses. We are studying the placement of organelles within cells and how they communicate to help better treat disease,” said Coskun.
Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 15 ISACs use small immuno-agonist molecules conjugated to the antibody to boost the immuneresponse while minimising toxicity.
There are a few approved therapies for DMD including four exon-skipping drugs and one AAV-microdystrophin drug, which uses a shortened version of dystrophin. AAV-based therapies often can’t be dosed more than once due to concerns about an immuneresponse. This may lead to a more robust restoration of muscle function.
As we explore translatability, technological advancements and the integration of artificial intelligence (AI), we envision the potential role of PDOs throughout the entire medicine creation pipeline, from target identification to personalised clinical treatments, ultimately reducing costs and improving patient outcomes.
Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. 2 It is this complexity that necessitates powerful, targeted combination therapies.
Scientists at the University of California, San Francisco (UCSF) have been exploring this question, and their recent breakthrough will focus on the treatment of conditions such as eczema and allergies. In the absence of IL-31, these nerve cells failed to control the immune system, leading to unchecked inflammation.
In pregnant individuals, maternal autoantibodies can even attack the organs and tissues of the foetus, 1-9 Many of these diseases are rare, with no safe, targeted, advanced and effective treatment options approved for patients in need. Targeted therapies are designed to interfere with, or target, molecules such as proteins within the body.
While the journey to understand and treat this condition has been complex, recent innovations in vitiligo treatment have opened new doors, offering hope and improved outcomes for those affected. The Evolution of Vitiligo Treatments From ancient remedies to modern medicine, the treatment of vitiligo has undergone a remarkable transformation.
Targeting 4-1BB remained of interest to the immuno-oncology field as cell culture experiments and tumor models in mice suggested that robust anti-tumor immuneresponses could be triggered by anti-4-1BB antibody therapies. This is the T cell type most closely associated with anti-tumor immuneresponses.
We are in an era of immuno-oncology (IO) revolution with many approved therapies now available to treat a broad range of cancers. In this IO arena, we continue to search for additional treatments that can further benefit patients. While several subsets of T-cells exist, most can be classified as either CD8+ or CD4+ T-cells.
HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immuneresponses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immuneresponses and facilitating antibody production.
These connections provide all-too-important ‘reasons to believe’ for further investment and movement into earlier lines of therapy. However, despite this long winter, new approaches, ranging from CD3 bi-specifics, to cell therapies, to cancer vaccines, and more recent novel intracellular mechanisms have started to turn the tide.
The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.
This study, conducted using human cancer cells grown in a lab and mouse models mimicking human breast and lung cancer, revealed that the biomolecule treatment notably reduced tumour growth and increased survival rates. Tender elaborated that these results in immune cells ignoring the cancer rather than eliminating it, as they normally would.
Therefore, if you or a loved one is dealing with this rare condition, it’s essential to educate yourself about the condition and its potential treatments. This condition is thought to result from the immune system mistakenly attacking a thin layer of tissue below the outer layer of your skin. Radiation therapy.
Use of AAVnerGene capsid library provided to Neurophth for ophthalmic gene therapy.
Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immuneresponses and cost.
gene therapy company (hereafter Neurophth), and AAVnerGene Inc. ,
Diagnosis began to shift from a body-part basis to a molecular one, which I wrote about in “Mutation and location important in cancer treatment” for The Lancet in 2015. This removes the cancer’s blocking of the immuneresponse, so that T cells can fight the cancer.
Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. Molecular Therapy 20 , 1831-1832 (2012).
How does GigaGen’s single-cell discovery and development platform differ from traditional methods of producing polyclonal antibody therapies? Current methods for producing pAb therapies rely on regular plasma donations for their development. However, recombinant pAbs do not rely on continuous plasma sources for production.
Biogen today announced results of a new analysis of immuneresponse to the COVID-19 vaccine among people with multiple sclerosis (MS). Biogen today announced results of a new analysis of immuneresponse to the COVID-19 vaccine among people with multiple sclerosis (MS). Using data from the MS PATHS network in the U.S.,
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content